American College of Cardiology

Phase 2 data at ACC.25 provide further insight into the effects of lepodisiran on serum Lp(a) and other biomarkers of risk.

Intravenous iron supplementation was safe but showed mixed improvement in cardiovascular outcomes in the FAIR-HF2 trial at ACC.25.

Dapagliflozin lowered the incidence of all-cause death or worsening of heart failure versus standard care in the DapaTAVI trial at ACC.25.

A secondary analysis of FINEARTS-HF found consistent efficacy of finerenone on heart failure events and cardiovascular death, irrespective of AF status.

Bhatt examines the potential reversal of the antiplatelet effects of ticagrelor with bentracimab in the REVERSE-IT trial.

FARES-II trial shows 4-factor PCC is safer, reduces bleeding, transfusions, and complications vs frozen plasma in cardiac surgery.

Four-year results from SOUL at ACC.25 were the first to test the cardiovascular benefits of an oral GLP-1 RA in high-risk type 2 diabetes.

Data from the REVERSE-IT trial provide vital insight into the efficacy and safety of bentracimab as an FDA decision looms on the horizon.

The WARRIOR trial provides insight into intensive medical therapy in women with INOCA, but investigators caution limitations hinder the applicability of results.

Data from STRIDE at ACC.25 demonstrate semaglutide could provide even greater benefits in type 2 diabetes than previously known.

A look at 7 phase 2 and phase 3 trials with significant implications from ACC 2025's late-breaking and featured clinical research sessions.

Bhatt previews 3 late-breaking clinical trials being presented at this year's American College of Cardiology Annual Scientific Sessions.

Olezarsen shows promise in managing familial chylomicronemia syndrome, reducing triglycerides and acute pancreatitis events.

An ACC.24 analysis found a decline in TTM use post-2013 TTM trial, which investigators suggest indicates a potential misinterpretation of trial findings.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This edition focuses on 5 updates from the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions.

Laura Ross, PA-C, sits down for a Q&A on the HeartBeet Clinic and the role of reimbursable group visits in cardiovascular disease management and education.

A retrospective analysis of EHR data from ACC.24 provides insight into the effects of ARNI relative to ACEi/ARB in patients with newly diagnosed heart failure and an LVEF greater than 40%.

Safia Chatur, MD, discusses the results of a PARADIGM-HF analysis at ACC.24 examining the effects of ARNI use across the updated 2024 KDIGO Risk Classifications.

Ankeet Bhatt, MD, MBA, discusses a NUDGE-FLU analysis from ACC.24 examining effect of the CV gain-framed nudge in patients with and without history of AMI.

Ahmad Masri, MD, MS, discusses a study from ACC.24 examining trends in incidence and outcomes of emergency department visits related to hypertrophic cardiomyopathy from 2006 to 2019.

Sara Saberi, MD, discusses 1-year data from a cohort of 46 patients within the FOREST-HCM trial at ACC.24.

Deepak Bhatt, MD, MPH, MBA, provides a recap of top trials and new data from the American College of Cardiology's 2024 Annual Scientific Session.

A trio of experts discuss their perspectives on the recent advancement in pharmacotherapy within the management of hypertrophic cardiomyopathy.

A study on a web app for nonprescription statin therapy shows high concordance with clinician assessment, with 84.5% of participants achieving LDL-C reduction of 20% or more.

José López, MD, discusses a case series from ACC.24 related to leadless pacemaker extraction and reimplantation.

Christie Ballantyne, MD, discusses new data from the ROSE2 trial examining the potential synergistic effects of obicetrapib with ezetimibe in high-intensity statin users.

Martin Maron, MD, discusses the results of the IMPROVE-HCM trial and how it informs the community on the potential of ninerafaxstat.

Christie Ballantyne, MD, discusses data from the SHASTA-2 trial and how it informs the community on the potential of plozasiran in management of severe hypertriglyceridemia.

Veraprapas Kittipibul, MD, discusses an analysis of the TRANSFORM-HF trial at ACC.24.